Erasca remains a pre-revenue clinical-stage biotech with no product sales across ten reported quarters, and its trajectory hinges entirely on pipeline milestones. The company's cash position has eroded 75% from $172.8M in 2024Q2 to $42.5M in 2026Q2, while quar...
Price trend, volume and key moving averages
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 12, 2026 | -$0.14-25.7% vs -$0.11 | — vs — |
Q3 2026 Aug 11, 2026 | -$0.14-25.7% vs -$0.11 | — vs — |
Q2 2026 May 11, 2026 | -$0.60-438.0% vs -$0.11 | — vs — |
Q2 2026 Mar 12, 2026 | -$0.10+9.1% vs -$0.11 | — vs — |
SAN DIEGO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Erasca, Inc. (NASDAQ: ERAS) against certain of its officers and directors for alleged breaches of fiduciary duty.
Engineers Gate Manager LP bought a new position in Erasca, Inc. (NASDAQ: ERAS) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 87,380 shares of the company's stock, valued at approximately $1,601,000. Several other institutional investors and hedge funds have also added
MELBOURNE, Australia, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today issued a comparative analysis of its lead candidate PRP against recently reported clinical datasets from leading RAS-targeted programs, including Revolution Medicines' daraxonrasib (RASONQUE™; RMC-6236) and Erasca's pan-RAS molecular glue ERAS-0015.
Erasca, Inc. (ERAS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Benchmark ERAS against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Erasca, Inc. (ERAS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $15.55 | $5.4B | -35.34 | — | — | -33.27% | — | |
| $192.86 | $41B | -32.41 | — | — | -96.44% | — | |
| $123.96 | $9.13B | -21.19 | — | — | -42.78% | — | |
| $25.53 | $4.16B | -29.34 | 48.29% | -229.92% | -25.74% | — | |
| $122.06 | $10.04B | -33.08 | -16.72% | -285.41% | -21.5% | — | |
| $4.12 | $261.88M | -3.49 | 0.78% | -8.7% | -31.27% | — |
Erasca, Inc. (ERAS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Erasca, Inc. (ERAS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 11, 2026·SEC
Aug 10, 2026·SEC
Jul 14, 2026·SEC
Get notified when ERAS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Erasca, Inc. (ERAS) stock FAQ — growth, dividends, profitability & financials explained
Erasca, Inc. (ERAS) reported a net loss of $287.2M for fiscal year 2025.
Erasca, Inc. (ERAS) has a return on equity (ROE) of -33.3%. Negative ROE indicates the company is unprofitable.
Erasca, Inc. (ERAS) had negative free cash flow of $98.1M in fiscal year 2025, likely due to heavy capital investments.
